Ashraf Ibrahim

Summary

Affiliation: Los Angeles Biomedical Research Institute
Country: USA

Publications

  1. ncbi request reprint Comparison of antifungal treatments for murine fusariosis
    Brad Spellberg
    David Geffen School of Medicine at UCLA Los Angeles, CA, USA
    J Antimicrob Chemother 58:973-9. 2006
  2. pmc Pathogenesis of mucormycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California Los Angeles, 1124 W Carson St, Torrance, CA 90502, USA
    Clin Infect Dis 54:S16-22. 2012
  3. pmc Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?
    Ashraf S Ibrahim
    Division of Infectious Diseases, Harbor University of California at Los Angeles Medical Center, and the Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Med Mycol 47:592-600. 2009
  4. pmc Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Infect Dis 198:1083-90. 2008
  5. pmc Host cell invasion in mucormycosis: role of iron
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, United States
    Curr Opin Microbiol 14:406-11. 2011
  6. pmc The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis
    Ashraf S Ibrahim
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Infect Immun 74:3039-41. 2006
  7. pmc Comparison of lipid amphotericin B preparations in treating murine zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1573-6. 2008
  8. pmc Combination echinocandin-polyene treatment of murine mucormycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1556-8. 2008
  9. pmc The iron chelator deferasirox protects mice from mucormycosis through iron starvation
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 117:2649-57. 2007
  10. pmc The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    Mol Microbiol 77:587-604. 2010

Research Grants

  1. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
  2. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf S Ibrahim; Fiscal Year: 2010
  3. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf Ibrahim; Fiscal Year: 2007
  4. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
  5. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf Ibrahim; Fiscal Year: 2009

Collaborators

Detail Information

Publications53

  1. ncbi request reprint Comparison of antifungal treatments for murine fusariosis
    Brad Spellberg
    David Geffen School of Medicine at UCLA Los Angeles, CA, USA
    J Antimicrob Chemother 58:973-9. 2006
    ..Fusarium solani infections are notoriously difficult to treat. We compared the efficacy of polyenes and an echinocandin in treating murine fusariosis to identify the optimal therapeutic regimen...
  2. pmc Pathogenesis of mucormycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California Los Angeles, 1124 W Carson St, Torrance, CA 90502, USA
    Clin Infect Dis 54:S16-22. 2012
    ..Several promising therapeutic strategies in preclinical stages are identified...
  3. pmc Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?
    Ashraf S Ibrahim
    Division of Infectious Diseases, Harbor University of California at Los Angeles Medical Center, and the Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Med Mycol 47:592-600. 2009
    ..In conclusion, mucormycosis causes considerable cost to the US health care system. Targeted deployment of a niche vaccine could decrease infection rates and mortality from mucormycosis in a cost-effective manner...
  4. pmc Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Infect Dis 198:1083-90. 2008
    ....
  5. pmc Host cell invasion in mucormycosis: role of iron
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, United States
    Curr Opin Microbiol 14:406-11. 2011
    ..Ultimately, a superior understanding of the pathogenesis of mucormycosis will enable development of novel therapies for this disease...
  6. pmc The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis
    Ashraf S Ibrahim
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Infect Immun 74:3039-41. 2006
    ..Immun. 73:6191-6193, 2005). Here we show that the rAls1p-N vaccine also improves survival of outbred mice from disseminated candidiasis and that it is active against multiple virulent strains of C. albicans and non-C. albicans spp...
  7. pmc Comparison of lipid amphotericin B preparations in treating murine zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1573-6. 2008
    ..ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models...
  8. pmc Combination echinocandin-polyene treatment of murine mucormycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1556-8. 2008
    ..The efficacy of combination echinocandin-polyene therapy for mucormycosis is a class effect...
  9. pmc The iron chelator deferasirox protects mice from mucormycosis through iron starvation
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 117:2649-57. 2007
    ..As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted...
  10. pmc The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    Mol Microbiol 77:587-604. 2010
    ..oryzae. Thus, FTR1 is a virulence factor for R. oryzae, and anti-Ftr1p passive immunotherapy deserves further evaluation as a strategy to improve outcomes of deadly mucormycosis...
  11. pmc Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor University of Californa, Los Angeles Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 49:721-7. 2005
    ..oryzae in vivo and demonstrates an inverse dose-response effect. The potential for CAS to play a role in combination therapy against zygomycosis merits further investigation...
  12. pmc Posaconazole mono- or combination therapy for treatment of murine zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, 90502, USA
    Antimicrob Agents Chemother 53:772-5. 2009
    ..Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo...
  13. pmc Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute, Division of Infectious Diseases, Harbor UCLA Medical Center, 1124 West Carson St, St John s Cardiovascular Research Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:1768-70. 2011
    ..Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted...
  14. pmc The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    J Antimicrob Chemother 65:289-92. 2010
    ..We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy...
  15. ncbi request reprint Deferiprone iron chelation as a novel therapy for experimental mucormycosis
    Ashraf S Ibrahim
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Antimicrob Chemother 58:1070-3. 2006
    ..Other iron chelators, including deferiprone, which do not deliver iron to R. oryzae have been described. We therefore sought to determine whether iron-chelation therapy with deferiprone would effectively treat mucormycosis...
  16. pmc Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment
    Ashraf S Ibrahim
    Division of Infectious Diseases, Harbor UCLA Medical Center, 1124 West Carson St, RB2, Torrance, CA 90502, USA
    Curr Opin Infect Dis 21:620-5. 2008
    ..Iron acquisition is a critical step in the causative organisms' pathogenetic mechanism. Therefore, abrogation of fungal iron acquisition is a promising therapeutic strategy to impact clinical outcomes for this deadly disease...
  17. pmc Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Infect Immun 73:999-1005. 2005
    ..albicans and emphasize the potential for cell-mediated immune modulation as a prophylactic or therapeutic strategy against disseminated candidiasis...
  18. pmc Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro
    Ashraf S Ibrahim
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Bldg RB2, 1124 West Carson Street, Torrance, CA 90502, USA
    Infect Immun 73:778-83. 2005
    ..The fact that dead R. oryzae damage human endothelial cells may, in part, explain the lack of efficacy of fungicidal agents during clinical disease...
  19. pmc Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice
    Lin Lin
    The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, Torrance, California, USA
    PLoS Pathog 5:e1000703. 2009
    ..aureus and C. albicans from tissues. Thus, vaccine-mediated adaptive immunity can protect against both infections by targeting microbes for destruction by innate effectors...
  20. pmc Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice
    Brad Spellberg
    Division of Infectious Diseases, Harbor UCLA Research and Education Institute, St John s Cardiovascular Research Center, 1124 West Carson St, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 49:830-2. 2005
    ..05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone...
  21. doi request reprint Combination therapy for mucormycosis: why, what, and how?
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California at Los Angeles, 1124 West Carson St, Torrance, CA 90502, USA
    Clin Infect Dis 54:S73-8. 2012
    ..It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved...
  22. pmc The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
    Mingfu Liu
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 120:1914-24. 2010
    ..These results suggest a unique susceptibility of patients with DKA to mucormycosis and provide a foundation for the development of new therapeutic interventions for these deadly infections...
  23. pmc Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant
    Lin Lin
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Clin Vaccine Immunol 15:582-4. 2008
    ..Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants...
  24. pmc Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis
    Brad Spellberg
    Department of Medicine, Research and Education Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Infect Immun 71:5756-64. 2003
    ..Furthermore, the results provide in vivo confirmation that hyphal formation by C. albicans induces type 2 or IL-10-dominant host responses in tissues...
  25. doi request reprint Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target
    Guanpingsheng Luo
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    J Infect Dis 201:1718-28. 2010
    ..albicans, mediating resistance to phagocyte killing. Hyr1p is a promising target for vaccine or other immunological or small molecule intervention to improve the outcomes of disseminated candidiasis...
  26. pmc Novel perspectives on mucormycosis: pathophysiology, presentation, and management
    Brad Spellberg
    Department of Medicine, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, 1124 West Carson St RB2, Torrance, CA 90502, USA
    Clin Microbiol Rev 18:556-69. 2005
    ..The underlying principles of therapy for this disease remain rapid diagnosis, reversal of underlying predisposition, and urgent surgical debridement...
  27. ncbi request reprint Functional and structural diversity in the Als protein family of Candida albicans
    Donald C Sheppard
    St Johns Cardiovascular Research Center, Division of Infectious Diseases, Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, California 90502, USA
    J Biol Chem 279:30480-9. 2004
    ..albicans with an array of cell wall proteins capable of recognizing and interacting with a wide range of host constituents during infection...
  28. pmc Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae
    Ashraf S Ibrahim
    Harbor UCLA Research and Education Institute, Torrance, California 90502 UCLA School of Medicine, Los Angeles, California 90024, USA
    Antimicrob Agents Chemother 47:3343-4. 2003
    ..001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis...
  29. pmc Novel inhalational murine model of invasive pulmonary aspergillosis
    Donald C Sheppard
    St John s Cardiovascular Research Center, Division of Infectious Diseases, Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, California 90502, USA
    Antimicrob Agents Chemother 48:1908-11. 2004
    ..This procedure reproducibly delivered 1 x 10(3) to 3 x 10(3) conidia to the lungs. Lethal pulmonary IA developed over 2 weeks and was prevented by amphotericin B...
  30. ncbi request reprint Functional analysis of the Candida albicans ALS1 gene product
    Lucio Loza
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Harbor UCLA Research and Education Institute, 1124 West Carson Street, Torrance, CA 90502, USA
    Yeast 21:473-82. 2004
    ....
  31. ncbi request reprint Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts
    Brad J Spellberg
    Division of Infectious Diseases, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Leukoc Biol 81:632-41. 2007
    ..With continued development, this strategy to recapitulate neutrophil functions has the potential to serve as an effective alternative to granulocyte transfusions...
  32. pmc Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein
    Beverlie Baquir
    Divisions of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles UCLA Medical Center, USA
    J Infect Dis 201:473-7. 2010
    ..Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials...
  33. pmc Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson St, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 53:3122-5. 2009
    ..Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis...
  34. pmc Recent advances in the management of mucormycosis: from bench to bedside
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, RB2, Torrance, CA 90502, USA
    Clin Infect Dis 48:1743-51. 2009
    ..Prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis...
  35. ncbi request reprint A phagocytic cell line markedly improves survival of infected neutropenic mice
    Brad J Spellberg
    Los Angeles Biomedical Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Leukoc Biol 78:338-44. 2005
    ..With further refinements, activated HL-60 cells have the potential to overcome the technical barriers to neutrophil transfusions...
  36. ncbi request reprint Mice with disseminated candidiasis die of progressive sepsis
    Brad Spellberg
    Los Angeles Biomedical Research Institute, Division of Infectious Diseases at Harbor University of California at Los Angeles Medical Center, Torrance 90502, USA
    J Infect Dis 192:336-43. 2005
    ..However, despite decades of use, little is known about the physiological characteristics of the host in this model, and the cause of death remains unclear...
  37. pmc The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, University of California at Los Angeles Medical Center, Torrance, California 90502, USA
    Infect Immun 76:4574-80. 2008
    ..These data provide the foundation for cross-kingdom vaccine development against S. aureus and Candida, which collectively cause 200,000 bloodstream infections resulting in >/=40,000 to 50,000 deaths annually in the United States alone...
  38. pmc The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice
    Brad J Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Infect Immun 73:6191-3. 2005
    ..We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis...
  39. ncbi request reprint Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis
    Brad J Spellberg
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor University of California, Los Angeles UCLA Medical Center, Torrance, Torrance, CA 90502, USA
    J Infect Dis 194:256-60. 2006
    ..The rAls3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections...
  40. pmc Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California, Los Angeles, Medical Center, Torrance, CA 90502, USA
    J Infect Dis 197:967-71. 2008
    ..These data have significant implications for the development and interpretation of vaccine surrogate markers...
  41. pmc Recent advances in the treatment of mucormycosis
    Brad Spellberg
    The Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles UCLA Medical Center, 1124 West Carson Street, Torrance, CA, 90502, USA
    Curr Infect Dis Rep 12:423-9. 2010
    ..Large-scale, prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis...
  42. pmc Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans
    Yue Fu
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Eukaryot Cell 7:483-92. 2008
    ..Finally, these data validate the use of a conditional overexpression/suppression genetic strategy to identify candidal virulence factors...
  43. pmc Safety and efficacy of activated transfected killer cells for neutropenic fungal infections
    Lin Lin
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA
    J Infect Dis 201:1708-17. 2010
    ..Invasive fungal infections cause considerable morbidity and mortality in neutropenic patients. White blood cell transfusions are a promising treatment for such infections, but technical barriers have prevented their widespread use...
  44. ncbi request reprint Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene
    Yue Fu
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    FEMS Microbiol Lett 235:169-76. 2004
    ..These data demonstrate that we have cloned the gene encoding a R. oryzae high affinity iron permease and the putative rFtr1p is involved in assimilation of iron from iron-depleted environments...
  45. pmc Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis
    Caitlin Reed
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, University of California at Los Angeles Medical Center, Torrance, CA, USA
    Clin Infect Dis 47:364-71. 2008
    ..g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we recently began treating rhino-orbital-cerebral mucormycosis (ROCM) with combination polyene-caspofungin therapy...
  46. ncbi request reprint Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway
    Yue Fu
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Harbor UCLA Research and Education Institute, Bldg RB2, 1124 West Carson St, Torrance, CA 90502, USA
    Mol Microbiol 44:61-72. 2002
    ..cerevisiae Flo11p. Consistent with our in vitro results, Als1p was required for both normal filamentation and virulence in the mouse model of haematogenously disseminated candidiasis...
  47. pmc Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells
    Quynh T Phan
    Department of Medicine, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California, United States of America
    PLoS Biol 5:e64. 2007
    ..These results uncover the first known fungal invasin and provide evidence that C. albicans Als3 is a molecular mimic of human cadherins...
  48. pmc Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis
    Gunter Rieg
    Antimicrob Agents Chemother 50:2895-6. 2006
  49. pmc Effects of ploidy and mating type on virulence of Candida albicans
    Ashraf S Ibrahim
    Department of Genetics, Cell Biology, and Development, 320 Church St SE, Minneapolis, MN 55455, USA
    Infect Immun 73:7366-74. 2005
    ..These results show that the level of ploidy in Candida albicans can affect virulence, but the mating type configuration does not necessarily do so...
  50. pmc Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans
    Kurt A Toenjes
    Department of Microbiology and Molecular Genetics, 202 Stafford Hall, 95 Carrigan Dr, University of Vermont, Burlington, VT 05405, USA
    Antimicrob Agents Chemother 49:963-72. 2005
    ....
  51. ncbi request reprint Plasmids for expression of heterologous proteins in Rhizopus oryzae
    Jeffrey A Mertens
    Fermentation Biotechnology Research Unit, National Center for Agricultural Utilization Research, USDA, Agricultural Research Service, 1815 N University St, Peoria, IL 61604, USA
    Arch Microbiol 186:41-50. 2006
    ..Plasmid copy number had little impact on transcription or protein accumulation. These vectors should be useful for overexpression of heterologous proteins and potentially, metabolic engineering of Rhizopus strains...
  52. ncbi request reprint Native and modified lactate dehydrogenase expression in a fumaric acid producing isolate Rhizopus oryzae 99-880
    Christopher D Skory
    Bioproducts and Biocatalysis Research Unit, National Center for Agricultural Utilization Research, USDA, Agricultural Research Service, 1815 N University Street, Peoria, IL 61604, USA
    Curr Genet 52:23-33. 2007
    ..Additionally, transformed isolates grown with glucose accumulated up to 27 g lactic acid/l with a concurrent decrease in fumaric acid, ethanol, and glycerol compared with the untransformed and vector-transformed control strains...
  53. pmc Cdc42p GTPase regulates the budded-to-hyphal-form transition and expression of hypha-specific transcripts in Candida albicans
    Alysia L VandenBerg
    Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA
    Eukaryot Cell 3:724-34. 2004
    ..These data indicate that Cdc42p-dependent signaling pathways regulate the budded-to-hypha-form transition and the expression of hypha-specific genes...

Research Grants7

  1. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
    ..Furthermore, the genetic construct targeting ATAK cells to Candida can easily be adapted to any other pathogen against which a MAb has been raised. ..
  2. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf S Ibrahim; Fiscal Year: 2010
    ..Completion of the proposed studies will enable investigation of treatments that block R. oryzae uptake of iron. ..
  3. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..Completion of the proposed studies will enable investigation of treatments that block R. oryzae uptake of iron. ..
  4. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..Finally, the results of the current studies will be crucial to prioritizing antifungal strategies and study design for possible future clinical trials of patients infected with this extraordinarily deadly disease. ..
  5. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf Ibrahim; Fiscal Year: 2009
    ..Completion of the proposed studies will enable investigation of treatments that block R. oryzae uptake of iron. ..